Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial

Ji, LN; Gao, LL; Jiang, HW; Yang, J; Yu, L; Wen, J; Cai, CH; Deng, H; Feng, LQ; Song, BL; Ma, QY; Qian, L

Ji, LN (通讯作者)，Peking Univ Peoples Hosp, Dept Endocrinol & Metab, Beijing, Peoples R China.;Qian, L (通讯作者)，Innovent Biol Inc, Suzhou, Peoples R China.

ECLINICALMEDICINE, 2022; 54 ():

Abstract

Background Mazdutide (also known as IBI362 or LY3305677), a novel once-weekly glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, achi......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索